Clinical research - Press Releases

Date	Title	Company
01-Dec-2022	The Mobile Health/Central Lab Interface, an opportunity for DCT efficiency	mdgroup
29-Nov-2022	Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team	Rewind Therapeutics
24-Nov-2022	Allero Therapeutics Receives EIC Horizon Grant to Advance Treatment of Celiac Disease	Allero Therapeutics
23-Nov-2022	HpVac Appoints Joana Vitte, MD, PhD, as Chief Scientific Officer	HpVac SA
23-Nov-2022	Clinion Achieves GDPR Compliance, continuing its commitment to data privacy and security	Clinion
19-Nov-2022	AJG publishes data from HighTide Therapeutics' Phase 2 study of HTD1801 Treatment in Adults with PSC	HighTide Therapeutics
17-Nov-2022	Grant Avenue Capital Launches Helios Clinical Research	Grant Avenue Capital
17-Nov-2022	Velocity Clinical Research expands to UK	Velocity Clinical Research
16-Nov-2022	Enterome announces presentation of data from ongoing Phase 1/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022	Enterome
15-Nov-2022	ADVANCED CLINICAL LAUNCHES REFRESHED BRAND AND WEBSITE	ADVANCED CLINICAL
15-Nov-2022	Eremid® Genomic Services receives CLIA accreditation for its new clinical genomics laboratory	Eremid® Genomic Services
11-Nov-2022	Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy	Novotech Health Holdings Pte Ltd
10-Nov-2022	ICR urges continued negotiation after NICE rejection of olaparib for early breast cancer	The Institute of Cancer Research
10-Nov-2022	Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe	Minoryx
10-Nov-2022	MHRA Approves First New Vaccine in a Decade to Protect Children Against Pneumococcal Diseases, including Pneumonia.	MHRA
10-Nov-2022	Over 7% of pharmaceutical drugs go to waste as supply chain managers bemoan damaged and excess inventory	Little Fires
10-Nov-2022	Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis	UCB
10-Nov-2022	Nephrology and Urology Devices Market is estimated to be US$ 8.98 billion by 2030 with a CAGR of 6.7% during the forecast period 2030	Prophecy Market Insights
09-Nov-2022	UCB Reinforces Commitment to Rheumatology with 15 Abstracts including New Late-Breaking Data at ACR Convergence 2022	UCB
09-Nov-2022	Brandon Capital Invests in Neuroscience Company NRG Therapeutics	NRG Therapeutics